99 related articles for article (PubMed ID: 27023694)
1. Health Resource Utilization and Cost for Patients with Incontinent Overactive Bladder Treated with Anticholinergics.
Yehoshua A; Chancellor M; Vasavada S; Malone DC; Armstrong EP; Joshi M; Campbell K; Pulicharam R
J Manag Care Spec Pharm; 2016 Apr; 22(4):406-13. PubMed ID: 27023694
[TBL] [Abstract][Full Text] [Related]
2. Impact of Overactive Bladder Step Therapy Policies on Medication Utilization and Expenditures Among Treated Medicare Members.
Abbass IM; Caplan EO; Ng DB; Kristy R; Schermer CR; Bradt P; Collins JM; Chan WM; Suehs BT
J Manag Care Spec Pharm; 2017 Jan; 23(1):27-37. PubMed ID: 28025920
[TBL] [Abstract][Full Text] [Related]
3. Economic Burden of Illness in Adult Patients with Nocturia.
Dmochowski R; Brucker BM; Cole E; Kawahara S; Pulicharam R; Burk C; Tung A; Hale D
J Manag Care Spec Pharm; 2019 May; 25(5):593-604. PubMed ID: 30675816
[TBL] [Abstract][Full Text] [Related]
4. Impact of Coexisting Overactive Bladder in Medicare Patients With Dementia on Clinical and Economic Outcomes.
Caplan EO; Abbass IM; Suehs BT; Ng DB; Gooch K; van Amerongen D
Am J Alzheimers Dis Other Demen; 2019; 34(7-8):492-499. PubMed ID: 30966757
[TBL] [Abstract][Full Text] [Related]
5. Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis.
Chastek B; Carrera A; Landis C; Snyder D; Abedinzadeh L; Bancroft T; Nesheim J; Kennelly M; Staskin D
Adv Ther; 2024 May; 41(5):2086-2097. PubMed ID: 38520502
[TBL] [Abstract][Full Text] [Related]
6. Anticholinergic burden and comorbidities in patients attending treatment with trospium chloride for overactive bladder in a real-life setting: results of a prospective non-interventional study.
Ivchenko A; Bödeker RH; Neumeister C; Wiedemann A
BMC Urol; 2018 Sep; 18(1):80. PubMed ID: 30217174
[TBL] [Abstract][Full Text] [Related]
7. Impact of New Medications and $4 Generic Programs on Overactive Bladder Treatment Among Older Adults in the United States, 2000-2015.
Kinlaw AC; Jonsson Funk M; Conover MM; Pate V; Markland AD; Wu JM
Med Care; 2018 Feb; 56(2):162-170. PubMed ID: 29287033
[TBL] [Abstract][Full Text] [Related]
8. Health care resource utilization and costs associated with psychiatric comorbidities in adult patients with attention-deficit/hyperactivity disorder.
Schein J; Cloutier M; Gauthier-Loiselle M; Bungay R; Chen K; Chan D; Childress A
J Manag Care Spec Pharm; 2024 Jun; 30(6):588-598. PubMed ID: 38824634
[TBL] [Abstract][Full Text] [Related]
9. Overactive Bladder Prescribing Considerations: The Role of Polypharmacy, Anticholinergic Burden, and CYP2D6 Drug‒Drug Interactions.
Rutman MP; Horn JR; Newman DK; Stefanacci RG
Clin Drug Investig; 2021 Apr; 41(4):293-302. PubMed ID: 33713027
[TBL] [Abstract][Full Text] [Related]
10. Despite Recommendations, Anticholinergics Account for the Majority of Prescriptions to Treat Overactive Bladder in the United States.
Carr DN; Macharia A; Hacker MR; Winkelman WD
Urogynecology (Phila); 2023 May; 29(5):497-503. PubMed ID: 36730660
[TBL] [Abstract][Full Text] [Related]
11. Relationship Between Overactive Bladder and Bone Fracture Risk in Female Patients.
Mori S; Matsuo T; Honda H; Araki K; Mitsunari K; Ohba K; Imamura R
In Vivo; 2024; 38(4):2031-2040. PubMed ID: 38936892
[TBL] [Abstract][Full Text] [Related]
12. Assessing Health Care Burden in Glaucoma Patients with and Without Physical or Mental Comorbidities.
Serbin M; Devine B; Campbell J; Basu A
J Manag Care Spec Pharm; 2020 Mar; 26(3):325-331. PubMed ID: 32105174
[TBL] [Abstract][Full Text] [Related]
13. Who Progresses to Third-Line Therapies for Overactive Bladder? Trends From the AQUA Registry.
Jericevic D; Shapiro K; Bowman M; Vélez CA; Mbassa R; Fang R; Van Kuiken M; Brucker BM
Urol Pract; 2024 Mar; 11(2):394-401. PubMed ID: 38226920
[TBL] [Abstract][Full Text] [Related]
14. Real-World Evidence for Risk Factors of Bruises and Fractures from Falls in Patients with Overactive Bladder: A Medical Record Analysis.
Miyajima S; Omaru T; Ishii T; Arima H; Shibata Y; Izaki T; Haga N
Int J Clin Pract; 2023; 2023():3701823. PubMed ID: 38179145
[TBL] [Abstract][Full Text] [Related]
15. The impact of pharmacotherapy on sexual function in female patients being treated for idiopathic overactive bladder: a systematic review.
Evans CNB; Badenhorst A; Van Wijk FJ
BMC Womens Health; 2024 May; 24(1):290. PubMed ID: 38755593
[TBL] [Abstract][Full Text] [Related]
16. Anticholinergic Burden in Patients Treated for Overactive Bladder: Second-Line Therapy with Tibial Nerve Stimulation as a Solution.
Satyadev N; Ameen M; Do TH; Wang H
Int Urogynecol J; 2024 May; ():. PubMed ID: 38700729
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of real-world adherence and persistence patterns with vibegron, mirabegron, and anticholinergics in patients with overactive bladder: A retrospective claims study.
Chastek B; Carrera A; Landis C; Snyder D; Abedinzadeh L; Bancroft T; Nesheim J; Kennelly M; Staskin D
Neurourol Urodyn; 2024 May; ():. PubMed ID: 38720543
[TBL] [Abstract][Full Text] [Related]
18. The Use of Metformin in Overactive Bladder: A Retrospective Nested Case-control, Population-based Analysis.
Neu S; Matta R; Locke JA; Troke N; Tadrous M; Saskin R; Rebullar K; Nam R; Herschorn S
Urology; 2024 Jan; 183():70-77. PubMed ID: 37805050
[TBL] [Abstract][Full Text] [Related]
19. Cumulative Effects of Comorbid Burden and Overactive Bladder Symptoms on Fall Risk Among Older Women Seeking Treatment for Urogynecologic Conditions.
Fisher SR; Halder GE; Lee MJ; Allen L; Kilic GS
Urogynecology (Phila); 2023 Sep; 29(9):763-769. PubMed ID: 36946883
[TBL] [Abstract][Full Text] [Related]
20. The Impact of an Overactive Bladder Care Pathway on Longitudinal Patient Management.
Selle JM; Hanson KT; Habermann EB; Gebhart JB; Trabuco EC; Occhino JA; Young AD; Linder BJ
Urogynecology (Phila); 2024 Mar; 30(3):330-336. PubMed ID: 38484250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
